Aug. 15, 2002
ReNeuron Holdings Plc, a UK bio-pharmaceutical company which develops proprietary treatments for neurological disorders, has received a new European patent.
The European Patent Office has granted the company's patent application on the use of haematopoietic cells for transplantation into the brain.
According to ReNeuron this patent is of considerable importance given the increased commercial interest and recent scientific publication on the use of stem and progenitor cells derived from blood or bone marrow to treat neurological diseases.
The patent provides broad protection in the use of this technology to treat a variety of neurological diseases including Parkinson's disease, Huntington's disease and stroke.
(Dow Jones, 09 Aug 2002; ReNeuron Holdings Plc statement, 09 Aug 2002.)
M2 Europharma includes paraphrased and abstracted material with the source,
which is deemed to be reliable and duly identified. M2E is unable to provide
full-text copies of these original documents.
Copyright (c) 2002, M2 Communications